The Connection Between Depression, Inflammation and Obesity:  Implications for Treatment

Richard C. Shelton, M.D.

Introduction

Dr. Shelton attended medical school at the University of Louisville in Kentucky. He then travelled to Boston, MA, where he became a resident, and then Chief Resident at the Massachusetts Mental Health Center (now the Longwood Program), a teaching hospital of the Harvard Medical School. After residency, he was a research fellow at the National Institutes of Mental Health Intramural Program in Washington, D.C. before entering the faculty at Vanderbilt University in 1985. There he rose through the ranks to become the James G. Blakemore Research Professor and Vice Chair for Clinical Research in the Department of Psychiatry. He also became a professor in the Departments of Psychology and Pharmacology. Dr. Shelton joined the faculty of the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham in February 2012, as the Charles Byron Ireland Professor, Vice Chair for Research, and head of a newly formed Mood Disorders Research Center.

Learning Objectives

• Improve recognition and intervention for obesity in depressed patients.
• Increase monitoring of body weight, particularly visceral (intra-abdominal) fat mass and insulin levels in patients with mood disorders (over time).
• Incorporate a focus on obesity as an end point of the treatment of depression.      

Live webcast available at:  http://videos.mayo.edu/live

1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live.  MedHub will be implemented for all post presentation surveys.  Your name and e-mail are not linked to your evaluation. Identifiers are tracked separately for attendance records only.  To document your attendance, please send an email to rstpsychgr@mayo.edu. The badge reader should continue to be utilized for Gonda and Sister Helen Hayes locations.

Credit Statements

·         Mayo Clinic College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. 

·         Mayo Clinic College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.   

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None

Disclosure Summary

As a provider accredited by ACCME, Mayo Clinic College of Medicine (Mayo School of Continuous Professional Development), must ensure balance, independence, objectivity and scientific rigor in its educational activities.   Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity.  Safeguards against commercial bias have been put in place.  Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation.  Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentation.

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry: 

Dr. Shelton has a financial relationship with the following companies:  Alkermes, Inc., Allergan (Forest Pharmaceuticals), Assurex Health, Avanir Pharmaceuticals, Bristol-Myers Squibb Company, Cerecor, Inc., Clintara, LLC, Genomind, Janssen Pharmaceutica, Medtronic, Inc., MSI methylation Sciences, Inc., Naurex, Inc., Nestle Health (Pamlab, Inc.), Novartis, Inc., Otsuka Pharmaceuticals, Pfizer, Inc., Ridge Diagnostics, Shire Plc, Takeda Pharmaceuticals (Consultant and Grant/Research Support)

 No relevant financial relationship(s) with industry:
Brian Palmer, M.D., Michael Bostwick, M.D., Karen Grothe, Ph.D., Lois Krahn, M.D., Jarrod Leffler, Ph.D., Larissa Loukianova, M.D., Mary Machulda, Ph.D., Patricia Maus, Amber Pearson, Jeffrey Staab, M.D., Cosima Swintak, M.D., Kristin Vickers Douglas, Ph.D., Cynthia Harbeck-Weber, Ph.D., Michael Zaccariello, Ph.D., Georgina Rink

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

Dr. Shelton: Nestle Health - Deplin (l-methylfolate)

Questions regarding this program can be directed to rstpsychgr@mayo.edu